LoValtech
Startup
Lovaltech is at the forefront of innovating nasal vaccines with a unique approach that not only activates the classic humoral and cellular immune response but also triggers the mucosal compartment, offering immediate blockade against infectious agents. Established in 2022 as a University of Tours spin-off, Lovaltech was awarded the France 2030 Deeptech label, a testament to its revolutionary vaccination technology. Lovaltech flagship product, LVT-001, is a multivariant Covid nasal vaccine, stable at room temperature and needle-free, poised for entering Phase I/II clinical trials in 2024. The company is also expanding its R&D platform to tackle other infectious diseases and is open for partnerships in both non-human and non-infection applications.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events